Abiraterone And Endostar Effects The Level Of VEGF-A In Human Hormone Sensitivities Prostate Cancer Cell

Background:Prostate cancer is one of the most common male genitourinary malignancies.In recent years,the incidence rate in our country has been on an upward trend.Nearly one-half of these patients have been diagnosed late and have lost the chance of radical treatment.For prostate cancer,androgen can not only promote the growth of prostate cancer cells,it is also one of the important factors to upregulate VEGF?Vascular endothelial growth factor?.Angiogenesis is an important factor in the progression of malignant tumors,and VEGF plays an important role in this key factor.Recombinant human endostatin inhibits?Endostar?the growth of many tumors by downregulating VEGF expression and inhibiting angiogenesis,but the role of hormone-sensitive prostate cancer is not clear.Abiraterone is a first-line treatment for prostate cancer.It inhibits androgen synthesis by inhibiting CYP17?Cytochrome P450,family 17,17?-hydroxylase,17,20-lyase?.It is suggested that androgen can promote the expression of VEGF.Gradually become a first-line treatment for prostate cancer.At present,the effects of the anti-angiogenic drug Endi and the anti-androgen drug abiraterone on prostate cancer VEGF levels,especially the effect of the combination of the two drugs on VEGF production are rarely reported.Therefore,the aim of this study is to use abiraterone combined with Endostar intervene in prostate cancer LNCaP cells to detect the proliferation inhibition rate of LNCaP cells after combined therapy and the level of VEGF-A and PSA?Prostate specific antigen?in the culture supernatant.To explore the effect of two drugs on VEGF in LNCaP cells and provide more theoretical basis for anti-angiogenic therapy for prostate cancer.Objective:By detecting the combination of abiraterone and Endostar on the proliferation of prostate cancer LNCaP cells and the changes of VEGF-A and PSA levels in culture supernatants,the effect of two drugs on VEGF in LNCaP cells was explored,which is an anti-angiogenic therapy for prostate cancer patients.Practice provides a theoretical basis.Methods:The in vitro cultured LNCaP cells were divided into the control group without Abiraterone and Endostar intervention,and the different concentrations of Abiraterone,Endostar single drug group and Endostar combined abiraterone group.MTT assay was used to detect the proliferation inhibition rate of the drug.ELISA?Enzyme linked immunosorbent assay?was used to detect the levels of VEGF-A and PSA in culture supernatants of LNCaP cells treated with abiraterone,Endostar,and combination groups,and statistical analysis was used to analyze abiraterone.The effects of monotherapy and combination on the levels of VEGF-A and PSA in supernatants of LNCaP cells.Result:1.Compared with the control group,abiraterone and Endostar alone had inhibitory effects on the proliferation of prostate cancer LNCaP cells?P<0.05?in a concentration-dependent manner.The inhibitory rate of LNCaP cell proliferation was higher in the combination group than in the monotherapy group?P<0.05?.2.The IC₅₀0 of abiraterone on LNCaP cells was 14.50?mol/L,and the IC₅₀0 of Endostar on LNCaP cells was 13.58?L/ml.3.Compared with the control group,VEGF-A and PSA levels in the culture medium of prostate cancer LNCaP cells were significantly decreased?P<0.05?.And the inhibitory effect was concentration-dependent..4.The levels of VEGF-A and PSA in the combination group were significantly lower than those in the single drug group at 24 hours?P<0.05?.Conclusion:1.Abiraterone and Endostar had inhibitory effects on the proliferation of LNCaP cells in a concentration-dependent manner,and the combination of the two drugs had stronger inhibition on cell proliferation.2.Abiraterone and Endostar inhibit the secretion of VEGF-A and PSA from LNCaP cells in a concentration-dependent manner.3.The inhibitory effect of VEGF-A and PSA levels in the combination group was better than that of the single drug group at 24 hours.